NorrDia Unites with Nikkiso CRRT Business

Swedish company NorrDia AB is taking over the leadership of the Nikkiso CRRT business following an acquisition finalized 2024. Nikkiso Medical is a leading provider of products and solutions for CRRT globally.

CRRT is a treatment used for acute renal failure in critical care settings. The purpose of uniting the two companies is to create a new competitive player in the CRRT space. Moving forward as NorrDia, the company will continue to help professionals to improve quality of care to patients in the Acute segment.

Nikkiso, listed on the Tokyo Stock Exchange, recorded a total revenue of $1.17 billion in 2022, with approx. 7.5% attributed to its CRRT business. Nikkiso’s CRRT products, including machines and consumables, are primarily sold in China, Southeast Asia, and EMEA markets.

Based in Lund, Sweden, NorrDia AB was founded by a team of former Gambro and Baxter employees with extensive experience in renal care. The team has wide experience from all functional areas within MedTech and have developed, introduced manufactured and sold multiple products globally during their tenure in both Gambro and Baxter. 

The combination of the NorrDia experience and Nikkiso strong product portfolio and brand will enable us to create a strong position in the CRRT market. 

NorrDia’s Chairman, Klas Arildsson, comments, “Once again, we embark on a journey to improve care for patients with kidney failure. We believe there is a significant opportunity in the acute CRRT segment for a new supplier. Combining NorrDia’s expertise with Nikkiso’s CRRT portfolio and brand gives us a robust platform to claim this space. Our clinical competence, focus on reliability and simplicity will support healthcare professionals in enhancing patient care.”

About Nikkiso

Founded in 1953 and listed on the Tokyo Stock Exchange, Nikkiso contributes to sustainable development by delivering products across diverse sectors including energy, mobility, industrial equipment, medical devices, and healthcare. In 2022, Nikkiso reported a revenue of $1.17 billion, with the CRRT segment accounting for 7.5% of total sales. Nikkiso’s CRRT products, which include equipment, consumables, and dialysate, are essential in treating critically ill patients and are mainly sold in China, Southeast Asia, and EMEA.

About NorrDia

NorrDia is headquartered in Lund, Sweden, the centre of Medical and Biotech Innovation in the Nordics. It was founded 2021 by a group of business executives with a successful track record and experience from acute and chronic renal care in Gambro and Baxter. NorrDia is active in Renal care in both Acute and In-center settings. NorrDia also provides a portfolio of product solutions for Nutrition Delivery.